1. An immunogenic product containing IFNα coupled to a carrier protein molecule for use in treating an IFNα-related condition in a subject in need thereof, wherein a therapeutically effective amount of said immunogenic product for administration to a subject is more than 30 μg of immunogenic product per administration. 2. An immunogenic product according to claim 1, characterized in that the administration of a therapeutically effective amount of an immunogenic product prevents the onset of symptoms of a disease associated with excessive production of IFNα. 3. The immunogenic product according to claim 1, characterized in that the introduction of a therapeutically effective amount of an immunogenic product prevents the exacerbation of a disease associated with excessive production of IFNα. 4. The immunogenic product according to claim 1, characterized in that the conditions associated with IFNα include systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, vasculitis, HIV, type I diabetes, autoimmune thyroiditis and myositis. An immunogenic product according to any one of claims 1 to 4, characterized in that the therapeutically effective amount of an immunogenic product for administration to a subject is from 35 μg to 1000 μg of the immunogenic product per administration. An immunogenic product according to any one of claims 1 to 4, characterized in that the immunogenic product is administered to the subject at least twice a month. An immunogenic product according to any one of claims 1 to 4, characterized in that the immunogenic product is also administered to the subject at least once every three months. An immunogenic product according to any one of claims 1 to 4, characterized in that the immunogenic product is also administered to a subject when in a blood serum sample obtained from a subject1. Иммуногенный продукт, содержащий IFNα, соединенный с молекулой белка-носителя, для применения при лечении связанного с IFNα состояния у нуж
